Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

20.11.24	Pfizer Names Chris Boshoff Chief Scientific Officer And President, R&D, Effective Jan.1 (RTTNews)
20.11.24	Pfizer Announces New Chief Scientific Officer and President, Research & Development (Businesswire)
20.11.24	Pfizer's HYMPAVZI Approved In EU For Treatment Of Severe Hemophilia A Or B Without Inhibitors (RTTNews)
20.11.24	European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors (Businesswire)
14.11.24	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
04.11.24	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
29.10.24	Pfizer Again Boost FY24 Outlook - Update (RTTNews)
29.10.24	Pfizer Inc. Q3 Earnings Summary (RTTNews)
29.10.24	Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance (Businesswire)
24.10.24	CDC Panel Backs Expanded Use Of Pfizer's Pneumococcal Vaccine (RTTNews)
23.10.24	Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older (Businesswire)
23.10.24	FDA Okays Pfizer's RSV Vaccine ABRYSVO For Adults Aged 18 To 59 At Increased Risk For Disease (RTTNews)
22.10.24	U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease (Businesswire)
15.10.24	Tim Buckley Elected to Pfizer’s Board of Directors (Businesswire)
12.10.24	FDA Approves Pfizer's HYMPAVZI For Hemophilia A And B Treatment In Adults And Adolescents (RTTNews)
11.10.24	U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors (Businesswire)
10.10.24	Pfizer Reports Positive Topline Data From Phase 3 TALAPRO-2 Study Of Talzenna Plus Xtandi (RTTNews)
10.10.24	Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial (Businesswire)
10.10.24	Former Pfizer Executives Ian Read And Frank D'Amelio Decline Involvement With Starboard's Efforts (RTTNews)
09.10.24	Pfizer Declares Fourth-Quarter 2024 Dividend (Businesswire)
08.10.24	Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024 (Businesswire)
07.10.24	Starboard Takes $1 Bln Stake In Pfizer, Pushes For Major Changes : Report (RTTNews)
01.10.24	Pfizer's Total Interest In Haleon To Reduce From Approx. 22.6% To Approx. 15.0% (RTTNews)
25.09.24	Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets (Businesswire)
20.09.24	CHMP Recommends Marketing Authorization For Pfizer, BioNTech's Omicron KP.2-adapted COVID-19 Vaccine (RTTNews)
20.09.24	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union (Businesswire)
17.09.24	Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts (Businesswire)
14.09.24	Pfizer : Phase 2 Study Of Ponsegromab In Cancer Cachexia Meets Primary Endpoint (RTTNews)
14.09.24	Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia (Businesswire)
14.09.24	Pfizer's BRAFTOVI + MEKTOVI Delivers Long-Term Benefits In BRAF V600E-Mutant NSCLC (RTTNews)
14.09.24	Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer (Businesswire)
11.09.24	Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024 (Businesswire)
06.09.24	Basilea Receives $25 Mln Milestone Payment Following Strong Cresemba Sales Performance In Europe (RTTNews)
03.09.24	Pfizer, Valneva Report Further Positive Phase 2 Booster Results For Lyme Disease Vaccine Candidate (RTTNews)
01.09.24	Weekly Biotech Buzz: BMRN Cuts Jobs, FDA Approves New Mpox Vaccine, MRK Halts 2 Keytruda Studies (RTTNews)
28.08.24	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
27.08.24	Pfizer Launches Digital Platform PfizerForAll (RTTNews)
27.08.24	Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare (Businesswire)
25.08.24	Weekly Biotech Buzz: AADI Trims R&D Jobs, JNJ Loosens Purse Strings, FDA Snubs REGN's Myeloma Drug (RTTNews)
23.08.24	FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants (RTTNews)
23.08.24	Pfizer, BioNTech Obtain FDA Approval & Authorization For Omicron KP.2-adapted COVID-19 Vaccine (RTTNews)
22.08.24	Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine (Businesswire)
18.08.24	Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out (RTTNews)
16.08.24	Pfizer, BioNTech Announce Top-line Results In Phase 3 Trial Of MRNA-based Combination Vaccine (RTTNews)
16.08.24	Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age (Businesswire)
12.08.24	Pfizer's RSV Vaccine ABRYSVO Shows Positive Results In Phase 3 Study In Immunocompromised Adults (RTTNews)
12.08.24	Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults (Businesswire)
04.08.24	Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid (RTTNews)
31.07.24	ViiV Healthcare Reports Positive Data For 2-Drug Regimen DOVATO In HIV-1 Treatment (RTTNews)
30.07.24	Pfizer Boost FY24 Outlook - Update (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

22:34		Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone
17:58		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
17:58		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
17:58		SDAX aktuell: SDAX zum Handelsende auf grünem Terrain
17:58		Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen
17:58		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
17:56		Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an
16:17		Roche-Aktie stabil: Swissmedic genehmigt subkutane Version von Ocrevus

22:34

Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone

17:58

Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus

17:58

Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX

17:58

SDAX aktuell: SDAX zum Handelsende auf grünem Terrain

17:58

Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen

17:58

Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone